Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant hereditary disorder associated with mutations of the MEN1 gene, which is characterized by combined tumors of the parathyroid glands, pancreatic islet cells, and the anterior pituitary. A significant number of patients with the clinical features of MEN1, however, do not show MEN1 mutations upon direct sequencing. We describe a young woman who fulfilled the clinical and biochemical criteria for MEN1 syndrome, but DNA sequencing did not indicate any MEN1 mutations. She developed a prolactin-secreting pituitary macroadenoma, primary hyperparathyroidism with parathyroid hyperplasia, pancreatic lesions, and two subcutaneous lipomas. Array comparative genomic hybridization (aCGH) analysis of peripheral blood DNA revealed a heterozygous germline deletion at 11q13.1 that spanned at least 22.23 kilobases and contained the entire MEN1 gene. Integrated aCGH and cytogenetic analyses of the adenoma and lipoma tissues revealed somatic inactivation of the wild-type MEN1 allele by different routes: the second hit of MEN1 recessive oncogenesis leading to adenoma implied a loss of heterozygosity, whereas a balanced translocation deleting the wild-type MEN1 allele primed the lipoma development. These findings show that aCGH is a valuable means of optimizing genetic testing in MEN1 patients which complements other technologic approaches to elucidating the pathologic mechanisms of MEN1 tumors. Keywords FISH, aCGH, MEN1, pituitary adenoma, lipoma ª 2011 Elsevier Inc. All rights reserved.
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Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant monogenic disorder with 95% penetrance that occurs in approximately 1/30,000 people and has an equal gender distribution (1e3). It is characterized by the development of parathyroid adenomas (90e97%), pituitary adenomas (15e50%), and duodenal and/or pancreatic neuroendocrine tumors (30e80%) (4, 5) . In addition to these major lesions, patients may develop adrenal or thyroid adenomas, bronchial or thymic carcinoid tumors, and (albeit less frequently) various non-endocrine tumors such as lipomas, angiofibromas, collagenomas, and leiomyomas (6, 7) . The clinical diagnosis is based on the presence of at least two of the three main MEN1-related tumors (8, 9) , and there are reports of both sporadic (de novo) and familial forms. Familial MEN1 is diagnosed in the setting of a MEN1 case and a first-degree relative with at least one of the main MEN1-related tumors; sporadic MEN1 when there is no family history of MEN1-related tumors (10) .
The MEN1 causative gene (11) has 10 exons and encodes a 610 amino acid protein known as menin, a ubiquitously expressed nuclear protein that interacts with a number of the proteins (12, 13) involved in transcriptional regulation, genome stability, and cell division and proliferation (14, 15) . MEN1 acts as a tumor suppressor in accordance with the "two-hit" model of hereditary cancer postulated by Knudson: the first hit is germline (inherited or developed during gametogenesis) and generally remains silent until the first tumor develops; the second hit leads to clonal expansion as a result of the somatic loss of the MEN1 wild-type allele in the cell target of neoplastic transformation (9, 16) .
More than 450 MEN1 germline mutations have been identified so far (http://www.hgmd.org) (14, 17) , mainly spread throughout the coding region. Most of them (>80%) are inactivating nonsense and frameshift mutations that lead to the premature truncation of menin, whereas whole or partial gene germline deletions are quite rare (1%) (14) . Nine of the reported deletions are intragenic, although a few encompass several exons and have been detected by various molecular genetic techniques [Southern blotting, reverse-transcriptase polymerase chain reaction, gene dose assays, and long-range polymerase chain reaction; reviewed in (18) ]. Only two patients have been found to be constitutive carriers of a larger deletion involving neighboring genes by means of a gene dosage assay and multiplex ligationdependent probe amplification (MLPA) (19, 20) .
MEN1 germline mutations are detected in about 68% of cases with a clinical diagnosis of familial MEN1, as well as in 26% of sporadic cases (21e23). The reasons for this low detection rate are the following: 1) gross deletions that are not picked up by direct DNA sequencing; 2) the presence of mutations in the non-coding regions of the gene, which are not routinely examined; 3) false-negative findings due to preferential allele amplification; and 4) locus heterogeneity.
We herein describe a female patient with the MEN1 syndrome who was negative for MEN1 mutations upon DNA sequencing, although array comparative genomic hybridization (aCGH) analysis showed that she carries an 11q13.1 germline deletion encompassing the entire MEN1 gene. She first came to clinical attention because of a prolactinsecreting pituitary macroadenoma and primary hyperparathyroidism with parathyroid hyperplasia but, during the follow-up, was found to have developed two subcutaneous lipomas and pancreatic lesions compatible with multiple localizations of a pancreatic neuroendocrine tumor.
Characterizing cryptic mutations in apparently mutationnegative patients is important because of its potential diagnostic value and the fact that it may help to improve patient management. Our findings indicate that aCGH is a useful means of identifying deletions that may be missed by conventional mutation analysis and can thus contribute toward optimizing the MEN1 mutation detection rate. Furthermore, integrating cytogenetic, FISH, and aCGH studies of lipoma and adenoma tissues can reveal the multiple routes underlying the "second hit" of MEN1 oncogenesis.
Materials and methods

Clinical report
The proband is a 23-year-old woman born of unrelated parents with no family history of endocrinopathy. Written informed consent for the research investigation, which was approved by the Ethical Clinical Research Committee of Istituto Auxologico Italiano, was obtained from one of the parents.
She was diagnosed as having MEN1 syndrome at the age of 11 years, when she showed slowed growth, no pubertal development, and wide incomplete bitemporal hemianopia. Magnetic resonance imaging (MRI) of the pituitary gland revealed a pituitary macroadenoma with horizontal, anteroposterior, and vertical diameters of 20, 19 and 24 mm, respectively. The tumor compressed and displaced the optic chiasm, but there were no signs of any extension into the cavernous sinuses.
Laboratory tests showed marked hyperprolactinemia (1800 ng/mL; normal values, 5e25 ng/mL), hypercalcemia, growth hormone (GH) deficiency, and a low level of insulin-like growth factor I (IGF-I). Treatment was started with the longacting dopamine agonist cabergoline, the dose of which was gradually increased to 3 mg/week. Prolactin (PRL) levels decreased to about 100 ng/mL and the visual field defect normalized, but a repeat MRI showed only marginal shrinkage of the top part of the tumor.
Thyroid and parathyroid ultrasonography revealed an apparently homogeneous thyroid parenchyma, but also a 13 Â 7-mm oval mass at the base of the right thyroid lobe that was suspected of being a parathyroid lesion. The results of adrenal and pancreas computed tomography (CT) were negative.
Thyroid scintigraphy Technetium-99m-methoxyisobutylisonitrile (MIBI) showed accumulation within the lower pole of the right thyroid lobe, thus confirming the presence of a parathyroid adenoma.
It was impossible to make a cytologic diagnosis on the basis of the findings of thyroid fine needle aspiration because the cell sample was inadequate, but high parathyroid hormone (PTH) levels (>2,000 ng/mL) were found in the liquid. Given the provisional diagnosis of primary hyperparathyroidism, the patient was clinically diagnosed as having MEN1 syndrome, although mutation screening of MEN1 exons 2e10 by means of denaturing gradient gel electrophoresis and direct sequencing was negative.
Total parathyroidectomy with the autografting of a small piece of parathyroid gland into the left forearm was performed at another hospital. The pathologic diagnosis was parathyroid hyperplasia.
Recombinant GH replacement therapy was considered because the persistent GH deficit led to stunted growth, but it was not started because of the presence of the pituitary tumor, which was subsequently removed by means of transsphenoidal surgery. After surgery, continuous treatment with cabergoline normalized the patient's PRL levels (20 ng/mL) and, as MRI showed that the pituitary tumor had been almost completely excised, GH replacement therapy was started.
During the next 2 years, PRL levels gradually increased to 65 ng/mL, and MRI showed that the pituitary mass was slowly re-growing despite the continuation of the cabergoline therapy. With the agreement of the patient and her parents, no radiation therapy was administered because of the fear of side effects, but the tumor was closely monitored with the aim of reserving the option of a second surgical procedure in the case of compressive symptoms or excessive tumor growth.
Three years later, when the patient was 14 years old, ultrasonography revealed a subcutaneous 3 Â 3.1-cm lipoma on the right thigh. This soon became larger, and another lipoma was found on the front wall of the left hemithorax. After surgical excision, the first lipoma was histologically classified as a spindle cell lipoma (a tumor characterized by the proliferation of collagen-forming spindle cells).
By the time the patient was 15 years old, spontaneous puberty had still not occurred because of the persisting hyperprolactinemia (PRL levels were about 100 ng/mL) or the destruction of the normal pituitary gland. As another thorough examination (including a total body CT scan and duodeno-pancreatic echo-endoscopy) did not reveal the presence of a neuroendocrine tumor, the patient was primed with estrogens to induce pubertal changes and the development of secondary sexual characteristics. At the end of the priming period, oral estrogens/progestins were started to treat secondary hypogonadism, and GH replacement therapy was discontinued.
During the next 4 years, the patient experienced the recurrence of mild hypercalcemia with borderline high PTH levels, her PRL levels gradually increased to 180 ng/mL, and the vertical diameter of the pituitary tumor increased to 18 mm. Another trans-sphenoidal surgical procedure was performed for the purpose of partial debulking, but a small portion of residual tumor remaining in contact with the optic pathway precluded the use of gamma knife radiosurgery. The patient refused fractionated radiotherapy, and she continued taking cabergoline at a dose of 3 mg/week.
When the patient was 22 years old, abdominal CT revealed the presence of small hypodense pancreatic lesions, suggesting a pancreatic neuroendocrine tumor. Cytologic examination of a specimen taken from the largest lesion under echo-endoscopic guidance (maximum diameter, w 1 cm) confirmed the existence of a non-functioning neuroendocrine tumor, and the patient was therefore treated subcutaneously (s.c.) with Long-Action Octreotide Formulation (octreotide LAR) 30 mg every 28 days.
At the time of the last follow-up examination, 1 year after starting octreotide LAR, there was no change in the size of the pancreatic masses, and no new lesions had appeared; the pituitary tumor was slowly re-growing at the same apparent speed as in previous years.
Conventional cytogenetics
The patient's peripheral blood lymphocytes and the cells of the first lipoma were cytogenetically analyzed using standard methods. A post-surgical sample of fresh lipoma tissue was immediately processed by means of direct and short-term cultures after treatment with pronase-E (1 mg/mL at room temperature for 15 minutes). The chromosomes were studied using the QFQ banding technique, and the karyotype was described in accordance with the ISCN (2009) (24) .
Fluorescence in situ hybridization (FISH)
FISH for chromosomes 11 and 3 was performed on metaphases using whole-chromosome painting (WCP) according to the manufacturer's protocols (Abbott Molecular, Des Plains, IL). To characterize the 11q breakpoint, two contiguous BAC clones (RP11-885P1 and RP11-548G17) located in band 11q13.1 were selected using the UCSC Genome Browser (http://www.genome.ucsc.edu/, released March 2006) and provided by Prof. M. Rocchi (University of Bari, Italy). The BAC FISH experiments were performed using the protocols of Lichter et al. (25) 
aCGH
Genomic DNA was extracted from the proband's blood and adenoma tissue using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany), as instructed by the manufacturer. Pooled DNA from the peripheral blood of 10 gendermatched healthy donors (Promega, Madison, WI) was used as a reference for the patient's peripheral blood and adenoma tissue DNA, and the DNA extracted from the patient's peripheral blood was then used as a second reference for the DNA extracted from the adenoma tissue.
Genomic DNA (3 mg) was hybridized to the 244K microarray (Agilent Technologies, Palo Alto, CA), which consisted of approximately 236,000 60-mer oligonucleotide probes covering the entire genome at an average spatial resolution of about 30 kilobases (kb), and was processed according to the manufacturer's instructions. Dye emission was captured by a dual-laser Agilent scanner, and the images were processed using Agilent Feature Extraction software 9.1, and analyzed with DNA Analytics 4.0 software. A log 2 ratio plot between the test and reference genomic DNA was assigned in such a way that any aberrations in the test DNA copy number at a particular locus were indicated by the deviation of the plots from a modal value of 0, and the calls were identified using the ADM-2 algorithm.
The text aberration summaries were analyzed to calculate the medium log 2 ratios of every copy number alteration, and distinguish mosaic and non-mosaic alterations. The expected log 2 ratio cut-off values for non-mosaic heterozygous and homozygous deletions are À1 and À4, respectively. The expected log 2 ratio cut-off values for non-mosaic duplications and triplications are þ0.5 and þ1, respectively. Loweraverage log 2 ratios identified cell mosaics: e.g., a log 2 ratio of À0.3 represented a cell mosaic of about 50% (50% anomalous and normal cells), as demonstrated by dilution experiments (not shown).
Results
Constitutional molecular karyotype of the MEN1 patient
Array CGH analysis of genomic DNA extracted from the patient's peripheral blood showed a heterozygous deletion on chromosome band 11q13.1 that spanned at least 22.23 kb (chr11:64320682-64342914 base pairs), and contained all of the MEN1 gene and the 5 0 end of the adjacent MAP4K2 gene (Figure 1) . The centromeric breakpoint mapped to within a 3.7 kb region between probes A_14_P135243 (normal) and A_16_P02458082 (deleted) (Chr11:64,316, 924-64,320,682 bp, UCSC, hg18), whereas the distal breakpoint mapped to within a 7.7 kb region between probes A_16_P02458112 (deleted) and A_16_P19263781 (normal) (Chr11: 64,342,914-64,350,624 bp, UCSC, hg18). Furthermore, the patient also carried three copy number polymorphisms (CNPs): a deletion on 11q11 (chr11:55134486-55187341) and a duplication on 14q11. Figure S1) .
No parental DNA was available for testing, although we did not expect to find the MEN1 deletion because they were both asymptomatic.
Pituitary adenoma characterization
The experiments were performed using two different references: the first was pooled gender-matched DNA from healthy controls, and the second was DNA extracted from the patient's peripheral blood to highlight tumor-specific rearrangements without the background of the patient's constitutive copy number variants. As expected, aCGH analysis of the adenoma tissue showed the germline deletion on chromosome band 11q13.1 in both experiments, but the log 2 ratio signal of <À1 indicated the presence of about 0.5 copies against the two copies present in the reference DNA (median log 2 ratio between À2 and À4; Figure 2, A and B) .
We also found that the CNP on 11q11 had the same MEN1 log 2 ratio profile shift to the left of À1 (median log 2 ratio between À2 and À4; see Supplementary Figures S1 A2 and S1 A3), whereas the shift profile of the two CNPs located on 14q11.2 and 15q11.2 was not different from that of the patient's blood (see Supplementary Figures S1 B2 and S1 C2 ).
There were also gross copy number aberrations (including the partial loss of 1p), losses of chromosomes 11, 17 18, and 22, as well as gains of chromosomes 1q, 5, 6, 9, 15, and X (Figure 3 ). In addition, aCGH analysis revealed cytogenetic heterogeneity within the tumor. As shown in Figure 3 , each of the chromosomes or chromosomal regions involved in the numerical aberrations showed a specific vertical up or down shift in the log 2 ratio profile, which indicated the presence of subclones in quantitatively different ratios. The prevalent chromosomal aberrations were the loss of 1p12-1pter, the loss of chromosomes 11 and 17, and the gains of chromosomes 6, 9, and 15, all of which indicate a high percentage of affected cells (Supplementary Figure S2) .
Lipoma cytogenetics and FISH characterization
Cytogenetic investigation revealed a 46,XX,t(3;11)(p21;q13) karyotype in all of the analyzed lipoma metaphases ( Figure 4A ), whereas the patient's constitutional karyotype looked normal.
Specific WCP 11 and WCP 3 paints confirmed the reciprocal translocation t(3;11)(p21;q13) ( Figure 4B ), and FISH analyses of tumor metaphases using chromosome 11q13.1-specific BAC probes made it possible to characterize the 11q translocation breakpoint. In particular, RP11-885P1 (which contains the MEN1 gene) gave only one signal on the normal chromosome 11, thus revealing the presence of a concomitant deletion at the translocation breakpoint on the der(11) chromosome ( Figure 4C ). RP11-548G17, which is located contiguously distal to RP11-885P1, allowed the translocation breakpoint to be mapped to 11q13.1, proximally to its target region, as it gave a signal on chromosome der(3) and the normal chromosome 11 (Figures 4, D and E) . After the FISH study, the karyotype could be defined as 46,XX,t(3;11)(p21;q13). ish der(3)t(3;11)(p21;q13.1)(wcp3þ, wpc11þ,RP11-548G17þ),der(11)t(3;11)(p21;q13.1)(wpc3þ, wpc11þ,RP11-548G17-,RP11-885P1-).
Using RP11-885P1 on the metaphase spreads of the patient's peripheral blood, FISH gave two identically intense hybridization signals on chromosome 11 because the constitutive approximately 22.23 kb deletion was too small to be detected by means of BAC FISH.
Discussion
Array CGH analysis revealed a germline deletion of the entire MEN1 gene in our patient with sporadic MEN1 syndrome, who was negative for MEN1 mutations upon direct DNA sequencing. The deletion (!22.23 kb) may be longer at the ends because of the 11 kb gaps between the flanking oligonucleotides showing a normal hybridization signal and those delimiting the deletion. Interestingly, both of the gap Figure 1 Array CGH detection of a MEN1 gene deletion. The array profile concentrated on a 355 kb window within the 11q13.1 interval containing the MEN1 deletion, and scatter plot analysis revealed a deletion in 11q13.1 (a horizontal shift to the left of 0). Each point represents a single probe. The log 2 ratio was plotted for all of the oligonucleotide probes on the basis of their chromosome positions. The figure shows the aberration calls identified using the ADM-2 algorithm (color-shaded areas).
regions not covered by the array oligonucleotide probes contain several Alu sequences belonging to the same subfamily that has been described previously as mediating the deletion in MEN1 patients (19) .
Array CGH analysis of the pituitary adenoma revealed the absence of MEN1 alleles in at least some tumor cells because the median log 2 ratio of between À2 and À4 indicates the presence of about 0.5 copies, against the two copies in the reference DNA. In addition, a CNP on 11q11 (which involves an olfactory receptor cluster) had the same MEN1 profile shift (see Supplementary Figure 1A ), but not the two CNPs located on chromosomes 14 and 15 (see Supplementary Figure 1 , B and C). Moreover, in line with previous CGH findings concerning MEN1 syndrome-related pituitary tumors (27) , aCGH showed that the entire chromosome 11 was lost in a large number of cells.
Loss of the wild-type MEN1 allele can be driven by at least three mechanisms: 1) the loss of a whole chromosome 11 as a result of mitotic nondisjunction; 2) the loss of chromosome 11 followed by reduplication; and 3) mitotic recombination proximal to the 11q11 olfactory receptor cluster. The hypothesis that best fits our overall results is the loss of the The cytogenetic heterogeneity in the tumor revealed by aCGH analysis bears witness to clonal evolution, and the additional large copy number aberrations correlate well with previous aCGH and FISH findings (27e32). In particular, the three chromosomal aberrations observed in a large number of cells (the 1p12w1pter and chromosome 11 and 17 losses) coincide with the most frequent cytogenetic changes identified in previous studies (27, 28) .
The aCGH findings indicate a hyperdiploid karyotype, but do not correlate with the complex karyotype (56w79,XX,þX [2] ,þ1 [3] ,þ7 [2] ,þ8 [3] ,þ9 [3] ,þ11 [3] ,þ13 [2] ,þ14 [3] ,þ16 [3] ,þ20 [3] ,þ22 [2] [cp3]; this suggests a near-triploid set, which has been identified previously by karyotyping, although restricted to only three metaphases (33) .
Cytogenetic and FISH studies of the lipoma identified a t(3;11)(p21;q13) and a concomitant deletion involving the MEN1 gene at the translocation breakpoint on der (11) . BAC FISH did not reveal the small constitutive MEN1 deletion, but we hypothesize that the chromosome 11 involved in the translocation was the one carrying the wild-type MEN1 allele.
We could not characterize the 3p21 translocation breakpoint by means of BAC FISH because of the lack of metaphases. The cytogenetic data so far collected in the Mitelman Database of Chromosome Aberrations in Cancer (http:// www.cgap.nci.nih.gov/Chromosomes/Mitelman) show that chromosome deletions on 3p are frequent in the majority of solid tumors and many lymphoid malignancies. Moreover, a number of studies have demonstrated that the 3p21 band is highly prevalent in breakage-prone tumors (34) , probably because of its intrinsic fragility (35) .
In conclusion, detecting gross deletions in the MEN1 gene in apparently mutation-negative patients who are clinically suspected of being affected by MEN1 is important because of their potential diagnostic value and the contributions they can make to clinical management.
The results of our combined cytogenetic, FISH, and aCGH studies of the adenoma and lipoma tissues are consistent with the MEN1 recessive oncogenesis model, and highlight the multiple routes underlying the two hits of MEN1 oncogenesis.
